Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295836757> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W4295836757 endingPage "S1273" @default.
- W4295836757 startingPage "S1272" @default.
- W4295836757 abstract "Cancer patients have high increased risk of Venous Thromboembolism (VTE) and treatments have changed lately. ISTH guidelines suggest rivaroxaban and edoxaban as alternatives to Low Molecular Weight Heparin (LMWH) for VTE treatment in certain cancers with low bleeding risk. However, little is known about safety and effectiveness from observational studies in routine clinical use. This is one of 3 studies in the OSCAR program. Optimal anticoagulation treatment duration in cancer patients remains an open question. A minimum of 6 months is recommended or longer if VTE recurrence risk is high. Preventing VTE recurrence must be balanced with bleeding risk. Study aims are to compare incidence of recurrent VTE, bleedings (hospitalization) and death in patients on DOACs versus LMWH. Cohort study using Swedish national registers. All patients diagnosed with cancer 2013-2019 aged 18+ were identified in the Cancer Register and linked to Patient, Prescribed Drug, Population, and Cause of Death Registers. Eligible cancer patients with subsequent (index) VTE will be followed to recurrent VTE, bleeding, death, emigration or end of 2020. Up to 15 years look-back from index date will be used. Propensity score overlap weighting method will be used for confounding control for differences in covariates between DOAC and LMWH groups. In total 10403 individuals irrespective of VTE treatment were included, 55% men, 68% aged 65+, distributed by cancer site, type of VTE and selected comorbidities.Table: 1591PCancer site, VTE type at index and selected comorbiditiesCharacteristicValueProportion (%)Cancer siteOral/pharynx1.3Digestive31Respiratory/intrathoracic16Bone/articular cartilage0.2Melanoma1.7Mesothelial/soft tissue1.2Breast9.5Female genital8.1Male genital7.0Urinary6.3Eye, brain, CNS5.8Thyroid/endocrine0.9Ill-defined, secondary, unspecified4.5Lymphoid, hematopoietic, or related6.5Index VTE typeDVT39DVT+PE5PE56Comorbidities with 15 years look-backThrombophilia0.8Heart Failure7Diabetes14Hypertension43Bleeding (hospitalized)25 Open table in a new tab Analytic results will be presented at the ESMO conference." @default.
- W4295836757 created "2022-09-15" @default.
- W4295836757 creator A5006745772 @default.
- W4295836757 date "2022-09-01" @default.
- W4295836757 modified "2023-10-16" @default.
- W4295836757 title "1591P Swedish national population-based study of direct oral anticoagulants and low molecular weight heparin treatment for thromboembolism in cancer patients: The OSCAR SWE study" @default.
- W4295836757 doi "https://doi.org/10.1016/j.annonc.2022.07.1684" @default.
- W4295836757 hasPublicationYear "2022" @default.
- W4295836757 type Work @default.
- W4295836757 citedByCount "0" @default.
- W4295836757 crossrefType "journal-article" @default.
- W4295836757 hasAuthorship W4295836757A5006745772 @default.
- W4295836757 hasBestOaLocation W42958367571 @default.
- W4295836757 hasConcept C121608353 @default.
- W4295836757 hasConcept C126322002 @default.
- W4295836757 hasConcept C141071460 @default.
- W4295836757 hasConcept C2776301958 @default.
- W4295836757 hasConcept C2776884760 @default.
- W4295836757 hasConcept C2777557582 @default.
- W4295836757 hasConcept C2778661090 @default.
- W4295836757 hasConcept C2779161974 @default.
- W4295836757 hasConcept C2908647359 @default.
- W4295836757 hasConcept C71924100 @default.
- W4295836757 hasConcept C99454951 @default.
- W4295836757 hasConceptScore W4295836757C121608353 @default.
- W4295836757 hasConceptScore W4295836757C126322002 @default.
- W4295836757 hasConceptScore W4295836757C141071460 @default.
- W4295836757 hasConceptScore W4295836757C2776301958 @default.
- W4295836757 hasConceptScore W4295836757C2776884760 @default.
- W4295836757 hasConceptScore W4295836757C2777557582 @default.
- W4295836757 hasConceptScore W4295836757C2778661090 @default.
- W4295836757 hasConceptScore W4295836757C2779161974 @default.
- W4295836757 hasConceptScore W4295836757C2908647359 @default.
- W4295836757 hasConceptScore W4295836757C71924100 @default.
- W4295836757 hasConceptScore W4295836757C99454951 @default.
- W4295836757 hasLocation W42958367571 @default.
- W4295836757 hasOpenAccess W4295836757 @default.
- W4295836757 hasPrimaryLocation W42958367571 @default.
- W4295836757 hasRelatedWork W1746649267 @default.
- W4295836757 hasRelatedWork W1866105834 @default.
- W4295836757 hasRelatedWork W1920542504 @default.
- W4295836757 hasRelatedWork W2355421283 @default.
- W4295836757 hasRelatedWork W2494843548 @default.
- W4295836757 hasRelatedWork W2736900730 @default.
- W4295836757 hasRelatedWork W2741766490 @default.
- W4295836757 hasRelatedWork W2783289631 @default.
- W4295836757 hasRelatedWork W2970522902 @default.
- W4295836757 hasRelatedWork W3179735828 @default.
- W4295836757 hasVolume "33" @default.
- W4295836757 isParatext "false" @default.
- W4295836757 isRetracted "false" @default.
- W4295836757 workType "article" @default.